IL2 and neoplasm: Using the OMIQ platform and CyTOF, they characterized tumor immune infiltration and found that MC38 and YUMMER2.1 cells with B2M KO responded to anti-PD-1 treatment alone or in combination with IL-2 agonists, mediated by CD4+ T cells and NK cells.